ProfessorKen Walder

Australasian Society for Bipolar and Depressive Disorders, International Society for Bipolar Disorders, Biological Psychiatry Australia, Society for Mental Health Research, World Federation of Societies of Biological Psychiatry

European Association for the Study of Diabetes, American Diabetes Association, Australian Diabetes Society, International Association for the Study of Obesity, North American Association for the Study of Obesity, Australian Society for the Study of Obesity

1998 Fogarty Fellowship (NIH)

2006 Smart Geelong Network Biotechnology Researcher of the Year

Invited presentations at national and international conferences including:

40th Annual Society for Mental Health Research Conference, Noosa, November 2018. Invited seminar presentation: "Targeting microRNAs to screen for new compounds to treat bipolar disorder".

Australasian Society for Bipolar & Depressive Disorders Conference, Melbourne, November 2017. "Drugs used to treat bipolar disorder act via microRNAs to regulate expression of genes involved in neurogenesis and neurite outgrowth".

Biological Psychiatry Australia Annual Conference, Wooloongong, September 2016. "MicroRNA targets to repurpose drugs for bipolar disorder".

Australian Diabetes Society Annual Scientific Meeting, Sydney, August 2013. Invited seminar presentation: VVP808 and fatty liver disease.

Baker-IDI Research Institute Seminar Series, Melbourne, October 2011. Invited seminar presentation: Use of GES technology to discover a new insulin sensitising agent.

Frontiers in Obesity Research, Melbourne, September 2011. Invited seminar presentation: VVP808: A novel insulin sensitising agent.

University of Melbourne Department of Medicine Seminar Series, Melbourne, May 2010. Invited seminar presentation: VVP808: A novel insulin sensitising agent.

Monash University Obesity Diabetes Institute, Melbourne, June 2010. Invited seminar presentation: Mechanism of action of VVP808.

MSD Diabetes Meeting, Sydney, October 11-12, 2008. Symposium presentation: Overview of mitochondrial dysfunction in diabetes.

GTCbio 3rd Metabolic Diseases World Summit, San Diego, USA, November 1-2, 2007. Symposium presentation: Use of gene expression signatures to discover novel diabetes therapeutics.

ASSO 15th Annual Scientific Meeting, Canberra, Australia, August 31-September 2, 2007. Symposium presentation: The adipocyte as an endocrine organ.

2nd International Congress on Prediabetes and the Metabolic Syndrome, Barcelona, Spain, April 25-28, 2007. Symposium presentation: The mitochondrial protease PARL and type 2 diabetes.

2nd Scientific Meeting of the Asia-Pacific Diabetes and Obesity Study Group, Kyoto, Japan, August 26-7, 2006. Symposium presentation: CXS741, A Novel Secreted Protein Involved in the Pathogenesis of Obesity and Type 2 Diabetes.

1st Scientific Meeting of the Asia-Pacific Diabetes and Obesity Study Group, Kobe, Japan, August 20-1, 2005. Symposium presentation: Genetic variation in PSARL is associated with plasma insulin concentration.

Professor Walder serves as a reviewer for the following journals:

Acta Neuropsychiatrica, Molecular Neurobiology, International Journal of Neuropsychopharmacology, Biological Psychiatry.

Diabetes, Diabetologia, International Journal of Obesity, Molecular and General Genetics, Kidney International, Pancreas

Professor Walder regularly reviews research applications for national and international funding bodies, including NHMRC and ARC.

Recent discovery of several drugs that can be repurposed for the treatment of bipolar disorder and schizophrenia.

Chief Investigator in the new NHMRC funded Centre of Research Excellence for the Development of Innovative Therapies for Psychiatric Disorders ($2.5M, 2019-2024).